Novavax Inc. shares touched a five-year high as investors assessed early data on its experimental vaccine for Covid-19.
The stock surged as much as 21%, after sinking in extended trading Tuesday. Novavax has rallied more than 4,300% so far this year on speculation about the potential for its vaccine.
